Stock AUROLAB6 AURO LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Auro Laboratories Limited

Equities

AUROLAB6

INE292C01011

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:43:40 17/05/2024 pm IST 		5-day change 1st Jan Change
226.8 INR +5.00% Intraday chart for Auro Laboratories Limited -15.12% +75.41%
30/03 Auro Laboratories Limited Announces Cessation of Kailash Chand Bubna as Independent Director CI
06/02 Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 536.9 370.5 196 505.5 625.1 340.5
Enterprise Value (EV) 1 610.9 417.9 177.2 428.8 710.8 386.8
P/E ratio 15.2 x 8.42 x 4.83 x 7.04 x 22 x 13.9 x
Yield - - - - - -
Capitalization / Revenue 1.32 x 0.79 x 0.45 x 0.93 x 1.23 x 0.64 x
EV / Revenue 1.5 x 0.89 x 0.4 x 0.79 x 1.4 x 0.73 x
EV / EBITDA 9.8 x 6.11 x 2.88 x 3.81 x 15.4 x 8.81 x
EV / FCF 54.1 x 30.4 x 3.29 x 9.01 x -4.13 x -8.98 x
FCF Yield 1.85% 3.29% 30.4% 11.1% -24.2% -11.1%
Price to Book 4.14 x 2.13 x 0.91 x 1.77 x 1.98 x 1 x
Nbr of stocks (in thousands) 6,233 6,233 6,233 6,233 6,233 6,233
Reference price 2 86.15 59.45 31.45 81.10 100.3 54.64
Announcement Date 13/08/18 10/08/19 04/09/20 06/08/21 24/06/22 16/05/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 407.9 468.2 437.9 542.5 508.7 528.9
EBITDA 1 62.33 68.42 61.59 112.4 46.25 43.93
EBIT 1 53.02 58.33 51.36 102.1 36.08 33.18
Operating Margin 13% 12.46% 11.73% 18.81% 7.09% 6.27%
Earnings before Tax (EBT) 1 47.27 60.69 56.42 105 38.74 34.46
Net income 1 35.3 43.99 40.54 71.8 28.45 24.42
Net margin 8.65% 9.4% 9.26% 13.23% 5.59% 4.62%
EPS 2 5.660 7.059 6.505 11.52 4.560 3.918
Free Cash Flow 1 11.28 13.73 53.84 47.58 -172.2 -43.08
FCF margin 2.77% 2.93% 12.3% 8.77% -33.85% -8.14%
FCF Conversion (EBITDA) 18.1% 20.07% 87.42% 42.33% - -
FCF Conversion (Net income) 31.97% 31.21% 132.8% 66.27% - -
Dividend per Share - - - - - -
Announcement Date 13/08/18 10/08/19 04/09/20 06/08/21 24/06/22 16/05/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 74 47.4 - - 85.7 46.3
Net Cash position 1 - - 18.8 76.6 - -
Leverage (Debt/EBITDA) 1.187 x 0.6921 x - - 1.852 x 1.053 x
Free Cash Flow 1 11.3 13.7 53.8 47.6 -172 -43.1
ROE (net income / shareholders' equity) 31.5% 29% 20.8% 28.7% 9.47% 7.43%
ROA (Net income/ Total Assets) 11.6% 11.4% 9.75% 17.2% 4.66% 3.74%
Assets 1 304.7 385.4 415.7 417.8 610.9 653.2
Book Value Per Share 2 20.80 27.90 34.50 45.90 50.60 54.90
Cash Flow per Share 2 2.880 5.390 8.080 17.40 8.360 2.870
Capex 1 18 16.2 6.72 3.75 46.1 40.7
Capex / Sales 4.41% 3.45% 1.54% 0.69% 9.06% 7.7%
Announcement Date 13/08/18 10/08/19 04/09/20 06/08/21 24/06/22 16/05/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
AURO LABORATORIES LIMITED Stock Auro Laboratories Limited
+75.41% 16.12M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AUROLAB6 Stock
  4. Financials Auro Laboratories Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW